CLINICAL TRIALS PROFILE FOR DEXAMETHASONE ACETATE
✉ Email this page to a colleague
All Clinical Trials for dexamethasone acetate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00003213 ↗ | Drugs to Reduce the Side Effects of Chemotherapy | Completed | Swiss Group for Clinical Cancer Research | Phase 3 | 1996-05-01 | RATIONALE: Antiemetic drugs may help to reduce or prevent nausea and vomiting in patients treated with chemotherapy. It is not known whether receiving dexamethasone with granisetron is more effective than receiving dexamethasone with metoclopramide for reducing the side effects of chemotherapy. PURPOSE: Randomized phase III trial to compare the effectiveness of dexamethasone with either granisetron or metoclopramide in patients treated with chemotherapy. |
| NCT00091260 ↗ | CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis | Completed | Celgene Corporation | Phase 2 | 2004-01-01 | RATIONALE: Drugs such as CC-5013 and dexamethasone may be effective in treating primary systemic amyloidosis. PURPOSE: This phase II trial is studying CC-5013 to see how well it works with or without dexamethasone in treating patients with primary systemic amyloidosis. |
| NCT00091260 ↗ | CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis | Completed | Vaishali Sanchorawala | Phase 2 | 2004-01-01 | RATIONALE: Drugs such as CC-5013 and dexamethasone may be effective in treating primary systemic amyloidosis. PURPOSE: This phase II trial is studying CC-5013 to see how well it works with or without dexamethasone in treating patients with primary systemic amyloidosis. |
| NCT00258245 ↗ | Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia | Completed | National Cancer Institute (NCI) | Phase 1 | 2005-05-01 | RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Ascorbic acid may help arsenic trioxide work better by making cancer cells more sensitive to the drug. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Thalidomide may stop the growth of cancer cells by stopping blood flow to the cancer. Giving arsenic trioxide and ascorbic acid together with bortezomib, thalidomide, and dexamethasone may stop the growth of and kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of arsenic trioxide when given together with ascorbic acid, bortezomib, thalidomide, and dexamethasone in treating patients with relapsed or refractory multiple myeloma or plasma cell leukemia. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for dexamethasone acetate
Condition Name
Clinical Trial Locations for dexamethasone acetate
Trials by Country
Clinical Trial Progress for dexamethasone acetate
Clinical Trial Phase
Clinical Trial Sponsors for dexamethasone acetate
Sponsor Name
